AlanHaruoBryceMD

Genitourinary Oncology

Chief Clinical Officer, City of Hope® Cancer Center Phoenix Professor, Department of Medical Oncology & Therapeutics Research with City of Hope Professor, Department of Molecular Medicine, Translational Genomics Research Institute (TGen)

Join to view full profile

Dr. Bryce is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bryce's full profile

Already have an account?

Office
14200 W. Celebrate Life Way.
Goodyear, AZ 85338
Phone+1 602-883-1259

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2006 - 2009
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2003 - 2006
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2003, MD
UCLABS, Biochemistry , 1994 - 1998

Certifications & Licensure

CA State Medical License 2009 - Present
AZ State Medical License 2011 - 2025
MN State Medical License 2004 - 2009
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab Start of enrollment: 2018 Apr 24
Completed
Phase 1, Phase 2
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Start of enrollment: 2018 Nov 26
Active, not recruiting
Phase 2, Phase 3
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 Start of enrollment: 2020 Jul 28
Recruiting
Phase 2
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) Start of enrollment: 2021 Aug 11
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer.
Francesca Zacchi, Wassim Abida, Emmanuel S Antonarakis, Alan H Bryce, Elena Castro
European Urology Oncology. 2024-12-04
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Confere...
Alan H Bryce, Neeraj Agarwal, Himisha Beltran, Maha H Hussain, Oliver Sartor
Cancer. 2024-12-01
What's in a Name? Why Words Matter in Advanced Prostate Cancer.
William K Oh, Neeraj Agarwal, Alan Bryce, Pedro Barata, Courtney Bugler
European Urology. 2024-10-28

Journal Articles

Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients with Hereditary Cancer Syndrome
Scott Okuno, Luke Mountjoy, Cameron S Thorpe, Edward D Esplin, Robert L Nussbaum, Alan H Bryce, Tanios S Bekaii-Saab, Aleksandar Sekulic, JAMA Oncology

Lectures

Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Clinical Hematology and Oncology 2013: The 10th Annual Mayo Board Review
Mayo School of Continuous Professional Development, Scottsdale, Arizona - 1/18/2013

Press Mentions

Rucaparib Bests Physician’s Choice for BRCA+ mCRPCFebruary 23rd, 2023
Rucaparib Improves Radiographic PFS in Prostate Cancer SubgroupFebruary 16th, 2023
Rucaparib Extends PFS in Advanced Prostate CancerOctober 8th, 2022
Join now to see all